

# Recall the FL basics before diving into FL breakthroughs at EHA with memo inHaematology's exclusive interviews and reports

## Epidemiology<sup>1</sup>

### Age-adjusted incidence


2.5 per 100,000 men and women per year

### Median age at diagnosis

64 years

### 5-year relative survival

2014 – 2020




## Genetic markers and their frequency in FL<sup>2-6</sup>

Genetic marker	Frequency	Clinical significance
t(14;18)(q32;q21)	~85%	key hallmark of FL
KMT2D	~72%	diagnostic
CREBBP	~65%	diagnostic, prognostic
EZH2	~25%	diagnostic, prognostic, guides treatment decisions
EP300 / MEF2B / ARID1A	~15% each	diagnostic, prognostic
CARD11	~12%	diagnostic, prognostic
FOXO1	~6%	diagnostic, prognostic
NOTCH2, DTX1, UBE2A, HIST1H1E, MYC, TP53, CCND3, GNA13, S1PR2, P2RY8, POU2AF1, CDKN2A/B loss		prognostic with respect to histological transformation

## Follicular Lymphoma International Prognostic Index (FLIPI)<sup>7</sup>

- Age >60 years
- hemoglobin <12 g/dL
- serum LDH > normal
- Ann Arbor stage III/IV
- number of involved nodal areas >4


## 5-year survival by FLIPI risk categories<sup>7-9</sup>



**Treatment choice** is guided by multiple factors and geared to each patient's situation. If the disease is confined to one area, radiation therapy may be recommended, whereas a "watch and wait" approach might be suitable in asymptomatic patients. However, when symptoms do develop, the NCCN guidelines for classic FL suggest different treatment regimens (see Figure).<sup>10</sup>

New investigational agents for FL that are currently being assessed in phase 2 and **phase 3** trials as monotherapies or in combination with other agents are alphabetically listed below:<sup>11</sup>

- anti-CD20 AB: **MIL62**
- ADCs: brentuximab vedotin, loncastuximab tesirine, polatuzumab vedotin, zilovertamab vedotin
- anti-CD161 AB: IMT-009
- anti-CD19 allogeneic CRISPR-Cas9-engineered T-cells: CTX112
- anti-CD19 AB: tafasitamab
- anti-PD-1 AB: pembrolizumab, retifanlimab, tislelizumab, toripalimab



- Bcl2i: venetoclax
- BTK degrader: BGB-16673
- BTKi: acalabrutinib, ibrutinib, DTRM-5555
- CAR T-cell therapies
- CD20×CD19 BsAB: IMPT-314
- CD20×CD3 BsABs: epcoritamab, glofitamab, **odronextamab**
- CD47 blocker: ALX148
- cereblon E3 ligase modulatory drug: BMS-986369
- chemotherapy: azacitidine
- Denileukin diftitox: E7777
- EZH1/2 dual inhibitor: valemetostat
- HDACi: abexinostat, chidamide
- IL-1 receptor antagonist: anakinra
- PI3Ki: BGB-10188, HMPL-689, IBI376, linnerlisibon, umbralisib
- PKCβi: MS-553
- SIRPa-IgG4-Fc: TTI-622
- SIRPa-IgG1-Fc: TTI-621
- vaccine: EO2463, PCV13
- XPO1i: selinexor

**Abbreviations:** BTK, Bruton's tyrosine kinase; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; DVP, cyclophosphamide, vincristine, prednisone; HDT/ASCR, high-dose therapy with autologous stem cell rescue; HCT, allogeneic hematopoietic cell transplantation

**References:** • 1 Stat Facts: NHL — Follicular Lymphoma. Accessed May, 15, 2024, <https://seer.cancer.gov/statfacts/html/follicular.html>. • 2 Jacobsen E. Am J Hematol. 2022 Dec;97(12):1638-1651. • 3 Brescia P, et al. Cancer Cell. 2018 Sep 10;34(3):453-465.e9. • 4 Sánchez-Beato M, et al. Clin Transl Oncol. 2024 May;26(5):1043-1062. • 5 Pastore A, et al. Lancet Oncol. 2015 Sep;16(9):1111-1122. • 6 Lees J, et al. Front Immunol. 2023 May 18;14:1179101. • 7 Dreyling M, et al. Ann Oncol. 2021 Mar;32(3):298-308. • 8 ESMO: International Prognostic Index for Follicular Lymphoma. Accessed May, 15, 2024, <https://oncologypro.esmo.org/oncology-in-practice/practice-tools/international-prognostic-index-tools-for-lymphoma/international-prognostic-index-for-follicular-lymphoma>. • 9 Sortais C, et al. Ann Hematol. 2020 Jul;99(7):1595-1604. • 10 National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version 2.2024 B-Cell Lymphomas. Accessed May 17, 2024, [https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf). • 11 Clinicaltrials.gov. (2024). Accessed: 17052024.